Compugen reports Q2 EPS (8c), consensus (9c)

Reports Q2 revenue $1.3M, consensus $3.95M. As of June 30, Compugen (CGEN) had approximately $93.9M in cash, cash equivalents, short-term bank deposits, and investment in marketable securities. “We continued to advance our immuno-oncology clinical and early-stage pipeline programs,” said Anat Cohen-Dayag, President and CEO of Compugen. “We dosed the first patient in MAIA-ovarian, our global adaptive platform trial evaluating COM701 as a single agent for maintenance therapy in patients with relapsed platinum sensitive ovarian cancer. In addition, we are looking forward to presenting a pooled analysis of previously presented data from our three Phase 1 trials evaluating COM701 in heavily pretreated platinum resistant ovarian cancer at ESMO 2025 in October. We are also progressing the Phase 1 trial for GS-0321 a potential first-in-class anti-IL18BP antibody licensed to Gilead.”